Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DOCK 180 Double Nickase Plasmid (h): sc-401387-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DOCK 180 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- DOCK 180 Double Nickase Plasmid (h) and DOCK 180 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting DOCK1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DOCK 180 Antibody (E-2): sc-514080
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DOCK 180 Double Nickase Plasmid (h) | sc-401387-NIC | 20 µg | $410.00 | |||
DOCK 180 Double Nickase Plasmid (h2) | sc-401387-NIC-2 | 20 µg | $410.00 |
DOCK1 encodes DOCK 180, an atypical guanine nucleotide exchange factor that activates Rac-family GTPases to coordinate actin cytoskeleton remodeling. Through interactions with adaptor proteins such as ELMO, DOCK 180 regulates integrin-dependent adhesion, lamellipodia formation, phagocytosis, and directed cell migration, integrating signals from receptor tyrosine kinases and chemokine pathways. This signaling axis supports processes including immune cell trafficking and epithelial dynamics, and dysregulation of DOCK1-dependent Rac signaling has been linked to invasive behavior and altered metastatic potential in multiple cancer contexts. DOCK1 activity is also studied in inflammatory and neurodevelopmental settings where cytoskeletal control and cell movement are central to phenotype.
DOCK 180 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the DOCK1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within DOCK1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt DOCK1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of DOCK1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.